Nuage Therapeutics receives €1.8 million to advance the development of its first oncology therapy targeting intrinsically disordered proteins

Nuage Therapeutics, a spinoff of the Institute for Biomedical Research (IRB Barcelona) headquartered at the Barcelona Science Park, has secured a capital injection of €1.8 million from CDTI Innovación through its Innvierte program, with participation from the international fund Sofinnova Capital X. This financial contribution will enable the Catalan biotech company to advance the development of new drugs targeting therapeutic targets traditionally considered intractable, such as intrinsically disordered proteins (IDPs), which are associated with severe diseases like cancer and have so far remained beyond the reach of conventional treatments.

The company has developed its own innovative technological platform capable of reconstituting these IDPs—which do not adopt defined three-dimensional structures—into structured secondary forms, opening a new avenue for the design of therapeutic molecules capable of interacting with them. This breakthrough represents a paradigm shift in drug discovery, as IDPs have historically been dismissed as viable targets due to their flexible nature and the difficulty of modulating their function with small-molecule compounds.

Currently led by Stuart Hughes, the company focuses its efforts on converting this technology into real therapeutic solutions for patients with unmet medical needs. With this new financing round, Nuage Therapeutics aims to accelerate the preclinical development of its first oncology drug candidate and progress toward regulatory and clinical phases.

Sofinnova Partners, the firm managing the Sofinnova Capital X fund, is one of Europe’s leading venture capital firms specialized in life sciences. With offices in Paris, London, and Milan, it boasts an international team of professionals with solid scientific, medical, and business experience dedicated to supporting projects with high innovation potential and global health impact.

CDTI Innovación’s support is part of its Innvierte initiative, a program aimed at fostering business innovation by co-financing technological projects in collaboration with private investors. This activity is channeled through Innvierte Economía Sostenible SICC S.M.E., S.A., a self-managed venture capital company supervised by the CNMV, of which CDTI is the sole shareholder.

This operation adds to previous investments in Nuage Therapeutics, including that of Asabys Partners, with an accumulated commitment from CDTI Innovación of nearly €3 million. With continued support from strategic partners, Nuage consolidates its position as one of the most innovative biomedical startups in the Catalan and Spanish ecosystem, offering a unique technological proposition aimed at tackling highly complex therapeutic challenges.